CBIO

Crescent Biopharma, Inc. (CBIO) - Q3 2025 10-Q Summary

Business Context and Reporting Period

Crescent Biopharma, Inc. is a preclinical-stage biotechnology company focused on developing novel therapeutics for solid tumors. The reporting period covers the three and nine months ended September 30, 2025. The company was formed via a reverse recapitalization with GlycoMimetics, Inc., consummated on June 13, 2025, and subsequently redomesticated to the Cayman Islands. Crescent has no products approved for commercial sale and has not generated any revenue to date.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no debt outstanding as of September 30, 2025, following the conversion of convertible notes into equity during the reverse recapitalization.

Material Changes vs. Prior Period

• Reverse Recapitalization and Financing: The most significant change was the June 2025 reverse recapitalization with GlycoMimetics and a concurrent Pre-Closing Financing that raised approximately $200 million (gross). This resulted in a substantial increase in cash balances from $34.8 million at December 31, 2024, to $133.3 million at September 30, 2025.
• Expense Growth: Operating expenses increased significantly compared to the period from inception (September 19, 2024) through September 30, 2024. Research and Development (R&D) expenses rose from $2.5 million to $20.3 million for the three-month period, driven by the advancement of programs CR-001, CR-002, and CR-003.
• Debt Elimination: Convertible notes totaling $37.5 million (plus accrued interest) outstanding at December 31, 2024, were converted into ordinary shares and pre-funded warrants in connection with the merger, resulting in zero long-term debt as of September 30, 2025.
• Share Structure: The company underwent a 1-for-100 reverse stock split and redomestication, changing its jurisdiction from Delaware to the Cayman Islands.

Guidance, Outlook, and Risks

Outlook and Milestones: Management expects existing cash to fund operations for at least twelve months from the filing date. The company plans to submit an Investigational New Drug (IND) application for its lead program, CR-001 (an anti-PD-1/anti-VEGF bispecific antibody), in the fourth quarter of 2025, with initial clinical data anticipated in the second half of 2026. An IND for CR-002 is expected in mid-2026.

Management Commentary: The company is heavily reliant on its partnership with Paragon Therapeutics, Inc. for discovery and development. Significant R&D costs are attributed to Paragon-related activities and third-party contract research organizations.

Risks and Contingencies:

• Capital Requirements: As a preclinical company with no revenue, Crescent faces a high risk of needing additional financing to continue operations. Failure to raise capital could force delays or discontinuation of programs.
• Development Risk: There is no assurance that clinical trials will be successful or that regulatory approval will be obtained. The company has not yet initiated any clinical trials.
• Intellectual Property: The company does not currently own any issued patents; its portfolio relies on in-licensed rights from Paragon.
• Third-Party Reliance: Operations depend on third parties for manufacturing (including WuXi Biologics) and clinical trials. Geopolitical tensions and potential U.S. legislation (e.g., BIOSECURE Act) regarding Chinese biotech companies pose supply chain risks.
• Related Party Transactions: A significant portion of R&D expenses ($19.2 million for the nine months ended Sept 30, 2025) is related to Paragon, a related party.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "at least twelve months" liquidity estimate given the high burn rate ($44.8 million cash used in operations for nine months).
• Paragon Dependency: Review the terms of the Paragon Option Agreements and License Agreements to understand milestone payment obligations (up to $22 million for CR-001 and $46 million for CR-002/CR-003) and royalty rates.
• CR-001 Clinical Plan: Confirm the timeline for the IND submission (Q4 2025) and the specific preclinical data supporting the decision to proceed, given the lack of historical clinical data for the company.
• Supply Chain Risks: Assess the impact of potential U.S. restrictions on Chinese biotech manufacturers (specifically WuXi Biologics) on the company's ability to produce clinical trial materials.
• Share Dilution: Analyze the impact of outstanding options, RSUs, and pre-funded warrants on future dilution, noting the significant number of shares reserved for issuance.